Biocon declares ₹0.50 per share final dividend for FY26

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Biocon declared a final dividend of ₹0.50 per equity share for FY26
  • Shareholders on record as of July 3, 2026, are eligible for the payout
  • The dividend was approved at the AGM held on August 6, 2026
  • Payouts have been remitted electronically to registered accounts
powered bylight_fuzz_icon
50508862

*this image is generated using AI for illustrative purposes only.

Biocon Limited has commenced the remittance of its final dividend for FY26. The payout of ₹0.50 per equity share was approved by members at the 48th Annual General Meeting held on August 6, 2026.

The company confirmed that dividends have been credited electronically to shareholders who registered their bank details with the Registrar & Share Transfer Agent or Depository Participants. The record date for eligibility was July 3, 2026.

Dividend Remittance Details

Shareholders holding equity shares on the record date are eligible for the payout. The face value of each equity share is ₹5. The company advised investors to verify the credit in their bank accounts.

Detail Information
Dividend Per Share ₹0.50
Face Value ₹5
Record Date July 3, 2026
AGM Date August 6, 2026
Remittance Mode Electronic

Shareholder Communication

For shareholders who have not registered an email ID but have provided a physical address, the company sent physical intimation letters dated September 9, 2026. These communications include specific details regarding the gross dividend, tax deducted, and net dividend credited.

Investors facing issues with dividend credits are instructed to contact KFin Technologies Limited, the company’s Registrar & Share Transfer Agent. Future correspondence should include the shareholder name and Folio Number or DPID & Client ID.

What the Numbers Show

The final dividend payout represents a return on capital for shareholders as of the mid-year record date. With the AGM approval finalized in August, the remittance process reflects the completion of the corporate action cycle for FY26.

Historical Stock Returns for Biocon

1 Day5 Days1 Month6 Months1 Year5 Years
-1.99%-4.56%-10.22%-2.39%+4.51%+4.73%

How does Biocon's ₹0.50 dividend payout compare to its historical dividend yield and peer averages in the biopharma sector?

What impact might this dividend distribution have on Biocon's free cash flow and capital allocation strategy for upcoming R&D projects?

Will Biocon maintain this dividend policy in FY27, or is there potential for an increase given the company's recent financial performance?

Biocon schedules investor roadshow in Mumbai on September 11

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Biocon Limited hosts an investor roadshow on September 11, 2026
  • Management meets analysts and institutional investors in Mumbai
  • Interactions include both one-on-one and group formats
  • No UPSI will be disclosed during the meetings
  • Schedule is subject to change based on exigencies
powered bylight_fuzz_icon
50414637

*this image is generated using AI for illustrative purposes only.

Biocon has scheduled an investor roadshow for September 11, 2026, in Mumbai. The company’s management will engage with analysts and institutional investors through both one-on-one and group interactions.

Meeting details

The event is classified as an investor roadshow under Regulation 30(6) of the SEBI Listing Regulations. Biocon has confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during these sessions. The schedule is subject to change based on exigencies from either the investors or the company.

Parameter Details
Event Investor Roadshow
Date September 11, 2026
Venue Mumbai
Interaction Type 1x1/Group, In-Person

The company issued the intimation on September 8, 2026, to both the Bombay Stock Exchange and the National Stock Exchange of India. Further details regarding the schedule are available on the company’s official website.

Historical Stock Returns for Biocon

1 Day5 Days1 Month6 Months1 Year5 Years
-1.99%-4.56%-10.22%-2.39%+4.51%+4.73%

What specific strategic updates or financial guidance is Biocon likely to present during the September 11 roadshow given the recent market sentiment?

How might institutional investor reactions to this roadshow influence Biocon's stock price volatility in the weeks following the event?

Are there any pending regulatory approvals or clinical trial results for Biocon's key pipeline assets that investors are expected to seek clarification on?

More News on Biocon

1 Year Returns:+4.51%